# A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

> **NCT04568434** · PHASE3 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Olezarsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04568434
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-10-17
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568434, "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04568434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*